Unlocking Bipolar Disorder: Exploring Diagnosis, The Spectrum, Coexisting Conditions, and Breakthrough Treatments

Summary of Key Findings

Area	Details
Modernized Diagnostic Framework	Bipolar disorder diagnosis now incorporates DSM‑5‑TR updates, including expanded specifiers and refined categories for greater accuracy.
Evidence‑Based Treatment Guidance	Summarizes latest CANMAT/ISBD guidelines, outlining first‑ to third‑line treatments tailored by illness phase.
Recognition of the Bipolar Spectrum	Bipolar disorder viewed as a spectrum; cyclothymia and subthreshold presentations noted as important but often overlooked.
High Burden and Illness Course	Bipolar disorder tends to be chronic and episodic with frequent relapses, substantial depressive periods, ongoing cognitive or functional issues, especially with early onset.
Suicide Risk and Protective Factors	Suicide risk is high; lithium remains the best-supported preventive treatment, complemented by psychosocial approaches.
Limits of Screening Tools	Instruments like the MDQ have moderate sensitivity, necessitating comprehensive clinical assessment for accurate diagnosis.
Impact of Comorbidities	Psychiatric comorbidities are common, complicate care, worsen outcomes, and require tailored treatment sequencing.
Treatment Sequencing Principles	Mood stabilization should precede treatment of comorbidities, and certain medications can destabilize mood if not properly sequenced.
Role of Psychotherapy and Lifestyle Interventions	Psychotherapy and lifestyle changes are essential for long-term management.
Collaborative and Trauma‑Informed Care	Best outcomes arise from shared decision-making, cultural sensitivity, trauma awareness, and integrated, individualized care.

Introduction

Bipolar disorder, formerly called manic depression, is a group of mood disorders marked by recurrent episodes of mania or hypomania and depression. These episodes entail significant changes in mood, energy, activity, and daily functioning (APA, 2022). Affecting over 1% globally, and more than 2% when including the broader spectrum, bipolar disorder is a major source of disability, especially among youth (Merikangas et al., 2011; Oliva et al., 2024). Proper understanding and evidence-based treatment can help many individuals lead fulfilling lives. Yet misconceptions remain widespread. This article provides an up-to-date, evidence-based summary of bipolar disorder, including diagnosis, the bipolar spectrum, comorbidities, and current treatments to inform and support those affected and their families.

Section 1: What Is Bipolar Disorder?

1.1 Definition and Types

According to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR), bipolar and related disorders encompass several distinct diagnoses (APA, 2022):

Disorder	Key Features
Bipolar I Disorder	At least one manic episode (7+ days or requiring hospitalization); major depressive episodes often occur but aren't required for diagnosis.
Bipolar II Disorder	At least one hypomanic episode (4+ days) and one major depressive episode; depressive periods can be severe.
Cyclothymic Disorder	Chronic shifts between hypomanic and depressive symptoms that don't meet full criteria; persists 2 years in adults (1 year in youth); can impact life quality and may progress to bipolar I or II.
Other Specified Bipolar and Related Disorder	Clinically significant symptoms not meeting other categories, such as brief (2–3 day) hypomania with depression.
Substance/Medication-Induced & Medical Condition-Related Bipolar Disorders	Symptoms linked to substance use, medications, or medical conditions.

The DSM-5-TR also includes clinically important specifiers, which further describe the course and features of bipolar episodes:

• With mixed features: Involves at least three symptoms from the opposite mood pole during a mood episode; associated with greater illness severity, higher suicidality risk, and complex treatment (Oliva et al., 2024; Yatham et al., 2021).

• With anxious distress: Marked by tension, restlessness, trouble concentrating, or fear of disaster; linked to worse symptoms and outcomes (Ejnpn, 2023).

• Additional specifiers: Include rapid cycling (four+ episodes/year), psychotic features, peripartum onset, seasonal pattern, and catatonia.

1.2 Symptoms and Characteristics

Bipolar disorder involves more than "highs and lows." Manic episodes include elevated or irritable mood, increased energy, less need for sleep, grandiosity, talkativeness, racing thoughts, distractibility, increased activity, and risky behavior. Hypomania presents similar but milder symptoms without significant impairment or psychosis. Depressive episodes feature persistent sadness, loss of interest, appetite and sleep changes, fatigue, guilt, trouble concentrating, and possible suicidal thoughts. Bipolar depression often includes hypersomnia, leaden paralysis, mood reactivity, and psychomotor slowing, which are seen more frequently than in unipolar depression (Huang et al., 2022).

Section 2: Epidemiology, Course, and Prognosis

2.1 Prevalence and Age of Onset

Bipolar I and bipolar II disorders together have a lifetime prevalence ranging from 0.4% to 1.1%, while broader bipolar spectrum disorders impact about 2.4% of people globally (Merikangas et al., 2011; Oliva et al., 2024). Since 1990, the prevalence of bipolar disorder has risen by approximately 59%, likely because of increased diagnostic awareness and shifting population demographics (Oliva et al., 2024). Typically, bipolar disorder develops at three main ages: around age 17, which accounts for roughly 45% of cases (early onset), and additional peaks occurring near ages 26 and 42 (Oliva et al., 2024). Early-onset cases are associated with greater disease burden and a higher risk of comorbid conditions. Most people experience bipolar disorder onset before age 25 (Huang et al., 2022).

2.2 Course and Functional Outcomes

Bipolar disorder is a chronic, episodic illness with frequent relapses. Studies show that people with bipolar I spend about 30% of their time in depression and 10% in mania or hypomania, while those with bipolar II are depressed over half the time and experience hypomania only 1.4% of the time (Huang et al., 2022). Stable mood states occur roughly half the time; the rest is dominated by depressive or subthreshold symptoms (Oliva et al., 2024). Relapse rates are high, with half experiencing another episode within two years. Neuroimaging reveals progressive brain changes like cortical thinning and reduced gray matter. Cognitive deficits, such as problems with attention, memory, executive function, and emotion regulation, often persist even during stable periods, impacting daily functioning (Oliva et al., 2024).

2.3 Suicide Risk and Protective Factors

Bipolar disorder carries a high suicide risk, with 30–50% of people attempting suicide and 5–20% dying by suicide (Oliva et al., 2024). Risk factors include mixed episodes, psychosis, substance use, history of attempts, early onset, and frequent depressive episodes (Huang et al., 2022; Oliva et al., 2024). Protective factors such as strong therapeutic relationships, psychoeducation, family support, and pharmacotherapy, especially lithium can help reduce risk (Yatham et al., 2018; Huang et al., 2022). Regular screening and safety plans are vital. Suicidal thoughts and behaviors in bipolar disorder are treatable, and immediate help should be sought if needed (e.g., the 988 Suicide and Crisis Lifeline in the U.S.).

Section 3: Diagnosing Bipolar Disorder

3.1 Challenges in Diagnosis

Diagnosing bipolar disorder is challenging, with an average five-to-seven-year delay from symptom onset (Oliva et al., 2024). Initial presentations often mimic unipolar depression, resulting in frequent misdiagnosis, as hypomanic episodes may go unrecognized. Comorbidities such as ADHD, borderline personality disorder, anxiety, and substance abuse complicate assessments. Treating misdiagnosed cases with antidepressants alone can induce mania or rapid cycling (Huang et al., 2022), and up to 40% of treatment-resistant depression may be hidden bipolar disorder. Indicators of bipolarity include family history, onset before 25, atypical depressive symptoms, psychotic features, antidepressant-induced agitation or resistance, brief recurrent depressions, mixed symptoms, and comorbid substance use.

3.2 Diagnostic Criteria and Screening Tools

Bipolar disorder is diagnosed clinically, as there are no definitive lab tests or biomarkers. Diagnosis relies on DSM-5-TR and ICD-11 criteria, with assessment including psychiatric and family history, substance use, medical conditions, and structured interviews such as SCID-5 or MINI. Screening tools like the MDQ and HCL-32 can help identify potential cases but are not diagnostic; the MDQ has moderate sensitivity and high specificity, especially in clinical settings, while the HCL-32 may better detect bipolar II. The WHO CIDI is suitable for primary care. Ultimately, comprehensive clinical evaluation is necessary, as positive screens require follow-up and negative results do not rule out the disorder.

Section 4: The Bipolar Spectrum

4.1 Understanding the Spectrum

The bipolar spectrum concept recognizes that mood disorders exist on a continuum, from severe cases like bipolar I disorder to milder forms such as cyclothymia. This view highlights that many people with significant distress do not meet full criteria for bipolar I or II, leading to underdiagnosis (APA, 2022). The DSM-5-TR addresses this by including "other specified" and "unspecified" categories, but some experts propose an even broader, dimensional approach focusing on predominant episode type, mood reactivity, and temperament. Such a perspective may improve treatment personalization (Oliva et al., 2024).

4.2 Cyclothymia: An Underrecognized Condition

Cyclothymic disorders involve chronic mood instability with recurring hypomanic and depressive symptoms that do not meet full criteria for major episodes. The pattern must last at least two years. Though considered "mild," cyclothymia often causes significant psychosocial problems like relationships and job instability and reduced quality of life. It can increase risk for bipolar I or II disorders and is frequently underdiagnosed, as its symptoms are mistaken for normal mood swings or personality traits. Clinicians should be alert to cyclothymia in patients with persistent mood instability, particularly those with a family history of bipolar disorder, as early recognition may reduce impairment and prevent progression.

Section 5: Bipolar Disorder Comorbidities

Psychiatric comorbidity is common in individuals with bipolar disorder; in fact, it is more the rule than the exception. Approximately 65% of people diagnosed with bipolar disorder also have at least one additional psychiatric condition, and nearly half present with three or more comorbidities (Oliva et al., 2024). The most prevalent comorbidities include anxiety disorders (affecting roughly 75% of those with bipolar I or II), substance use disorders (present in about 50% of bipolar I and 33% of bipolar II cases), as well as the specific conditions discussed below (Huang et al., 2022). These comorbidities contribute to worse clinical outcomes, increased risk of suicide, more complicated treatment requirements, and greater overall functional impairment.

5.1 ADHD and Bipolar Disorder

ADHD commonly co-occurs with bipolar disorder in adults, with 10–25% affected. Both conditions share symptoms, such as inattention, impulsiveness, hyperactivity, and sleep problems, which can complicate diagnosis. In ADHD, these symptoms are chronic and start in childhood; in bipolar disorder, they are episodic and mark a shift from baseline. ADHD symptoms persist after mood stabilization, offering diagnostic insight. Bipolar racing thoughts are usually coherent, while ADHD's wandering mind is unfocused. Family history and illness course aid differentiation. If both disorders exist, mood stabilization comes first, as stimulants for ADHD can worsen bipolar symptoms if not controlled. After stabilizing mood, ADHD treatments, including stimulants may be used with specialist oversight (Karaahmet et al., 2022; Perrotta et al., 2021; Schiweck et al., 2021).

5.2 OCD and Bipolar Disorder

Obsessive-compulsive disorder (OCD) co-occurs with bipolar disorder in about 6–16% of cases, and vice versa (Amerio et al., 2024). Having both disorders often means a more severe course, with frequent depression and treatment resistance. OC symptoms in bipolar disorder tend to worsen during depressive episodes and improve with mania or hypomania, unlike the typically chronic course of primary OCD. Treating these comorbidities is challenging, as standard OCD medications like SSRIs may destabilize mood, so mood stabilization is a priority. Atypical antipsychotics, particularly quetiapine, can help manage both conditions, while cognitive-behavioral therapy with ERP offers a safe non-drug option (Amerio et al., 2024; Elkholy et al., 2025).

5.3 Borderline Personality Disorder and Bipolar Disorder

Borderline personality disorder (BPD) occurs with bipolar disorder in around 15% of cases (Huang et al., 2022). Both share emotional dysregulation, impulsivity, relationship issues, and suicidality, and complicating diagnosis. Bipolar disorder features mood episodes lasting days to weeks, while BPD’s mood shifts are rapid and triggered by interpersonal stressors. Identity disturbance, chronic emptiness, unstable relationships, and abandonment fears are specific to BPD. Tools like the MSI-BPD aid differentiation (Huang et al., 2022). When both co-occur, treatment combines medication for bipolar disorder and psychotherapy such as DBT for BPD symptoms. Accurate assessment is vital: misdiagnosis can lead to unnecessary medication or delayed mood-stabilizing treatment (Asherson et al., 2023).

5.4 Autism and Bipolar Disorder

Autism spectrum disorder (ASD) and bipolar disorder often co-occur, though prevalence varies with sample type; about 2% in children and adolescents per Lukmanji et al. (2022), but rates may be higher clinically. Genetic research suggests shared risk factors. Diagnosis is complicated by overlapping symptoms like mood instability, irritability, impulsivity, sleep issues, and social challenges. Differentiating manic episodes from autistic behaviors requires thorough assessment and awareness of unique symptom presentations. Treatment options are limited due to exclusion from trials; standard therapies are used carefully, as ASD individuals may be sensitive to side effects. A gradual medication approach and ASD-specific supports are advised, although more research is needed.

5.5 Principles for Treatment When Multiple Conditions Co-Occur

When treating individuals with bipolar disorder and comorbidities, focus first on stabilizing mood, as episodes can complicate diagnosis and management. Assess comorbid conditions during stable periods. Prioritize safety by addressing urgent issues like suicidality and substance use before chronic concerns. Introduce treatments for comorbidities only after mood is stable, monitoring for drug interactions or risks. Choose medications that treat multiple conditions, when possible, such as quetiapine or lamotrigine, and avoid anything that might destabilize mood, like antidepressant or stimulant monotherapy and high-dose SSRIs. Psychotherapy should be included since it addresses comorbidities without increasing risk of mood instability.

Section 6: Treatment Strategies

6.1 Pharmacological Treatment

Pharmacotherapy is the foundation of bipolar disorder management. The CANMAT/ISBD guidelines from 2018, along with their 2023 evidence update, provide the most thorough and evidence-based framework for treatment currently available. These guidelines help clinicians select appropriate medications based on the phase of illness and individual patient factors.

Acute Mania

Line of Treatment	Agents
First-line	Lithium, quetiapine, divalproex, asenapine, aripiprazole, paliperidone, risperidone, cariprazine (either as monotherapy or in combination)
Second-line	Olanzapine, carbamazepine, ziprasidone, haloperidol, electroconvulsive therapy (ECT)
Third-line	Clozapine, tamoxifen (as PKC inhibitor), other agents with limited supporting evidence

For severe manic presentations, combination therapy involving a mood stabilizer plus an atypical antipsychotic may be required. Medications that have the potential to worsen or prolong mania, including antidepressants, should be discontinued. Early improvement—defined as at least a 10% reduction in symptoms by the first week of treatment—is a positive indicator of response. If minimal improvement is observed, clinicians should consider adjusting treatment by the second week.

Acute Bipolar Depression

Line of Treatment	Agents
First-line	Quetiapine (monotherapy), lurasidone (monotherapy or with lithium/divalproex), lithium, lamotrigine, adjunctive lamotrigine
Second-line	Divalproex, cariprazine, ECT
Third-line	Olanzapine/fluoxetine combination, other agents with limited evidence

Bipolar depression is typically more resistant to treatment than unipolar depression and is associated with a greater risk of suicide. Achieving full remission is critical because lingering depressive symptoms are linked to functional impairment and increased risk of relapse.

Antidepressant Use and Switch Risk

Antidepressants should not be used alone in bipolar disorder due to the risk of triggering mania or hypomania. When paired with mood stabilizers or atypical antipsychotics, most antidepressants are generally safe except for tricyclics and venlafaxine, which have higher risks and are usually avoided. Antidepressants should be avoided or used cautiously in those with rapid cycling, mixed features, or prior problems with these drugs. The ideal duration of antidepressant use after depression is uncertain. For treatment-resistant cases, ECT has the best results, while newer options like ketamine and esketamine show early promise without causing mania.

Maintenance Treatment

Line of Treatment	Agents
First-line	Lithium, quetiapine, divalproex, lamotrigine, asenapine, aripiprazole (monotherapy or combination)
Second-line	Olanzapine, risperidone (long-acting injectable), carbamazepine, paliperidone

Maintenance treatment is essential for bipolar disorder, as relapse rates are high without ongoing medication. Lithium remains the first-line mood stabilizer, effective in suicide prevention and neuroprotection, primarily preventing mania but requiring regular monitoring. Lamotrigine helps prevent depressive episodes and is generally well tolerated but needs slow titration and is less effective for mania. Quetiapine works across all phases of bipolar disorder but requires metabolic checks. Divalproex (valproate) prevents mania but is unsuitable for women of childbearing age due to teratogenic risks. Atypical antipsychotics like aripiprazole, asenapine, and olanzapine are maintenance options, though they carry risks such as weight gain and metabolic syndrome. Regional guidelines may vary based on drug approvals.

6.2 Non-Pharmacological Approaches

Evidence-Based Psychotherapies

Psychosocial interventions are essential for bipolar disorder treatment. Research shows psychoeducation, CBT, IPSRT, FFT, and Functional Remediation are all effective. Psychoeducation informs patients and families about the disorder and relapse prevention; group sessions perform as well as CBT. CBT helps with negative thinking, coping skills, and medication use, reducing relapses and depression. IPSRT stabilizes sleep and social routines to prevent mood episodes. FFT involves family for better communication and problem-solving, aiding young or newly diagnosed people. Functional Remediation uses structured exercises to improve daily functioning.

Lifestyle Interventions

Lifestyle modifications are integral to enhancing mood stability. Adhering to healthy sleep practices is essential, as disturbances in sleep can both precipitate and result from mood episodes. Ensuring consistent sleep–wake schedules constitute a key measure in reducing the risk of relapse. The use of substances such as alcohol, cannabis, and stimulants has been linked to poorer outcomes, increased frequency of mood episodes, and elevated suicide risk; thus, it is critical to evaluate and address substance use at each clinical encounter. Engaging in regular physical activity contributes not only to improved mood but also to cardiovascular health, which is particularly relevant given the heightened risk of heart disease among individuals with bipolar disorder. Establishing routines, including regular meals, social interactions, and structured work schedules, supports the maintenance of stable circadian rhythms.

Collaborative, Trauma-Informed, and Culturally Sensitive Care

Effective treatment for bipolar disorder depends on working together. Collaborating on decisions, building a trusting relationship, and respecting each person's unique background help improve medication use and overall results. It's important to remember that many individuals with bipolar disorder have a history of childhood trauma, which should guide treatment planning. Providing culturally sensitive care involves understanding how culture shapes symptoms, beliefs about illness, seeking help, and treatment choices.

Conclusion

Bipolar disorder is a complex, chronic condition impacting emotional, cognitive, social, occupational, and physical aspects of life. With accurate diagnosis and evidence-based pharmacological and psychosocial interventions, many individuals achieve clinical stability, meaningful recovery, and a high quality of life. Optimal management requires comprehensive understanding of the illness’s spectrum, consideration of comorbidities, and individualized care plans developed collaboratively with healthcare professionals. Ongoing advancements, including precision psychiatry, digital health initiatives, and innovative therapies, continue to enhance treatment outcomes. It is important to recognize that bipolar disorder does not define an individual; with appropriate support, self-awareness, and effective treatment, those affected can lead thriving, productive lives.

Frequently Asked Questions

1. What are the main types of bipolar disorder?

The DSM-5-TR identifies several bipolar disorder types: Bipolar I (at least one manic episode), Bipolar II (hypomanic and major depressive episodes), Cyclothymic Disorder (chronic mood changes over two years), and Other Specified Bipolar and Related Disorder (distressing symptoms not meeting full criteria). Substance- and medically induced conditions are categorized separately (APA, 2022).

2. How is bipolar disorder diagnosed?

There are no definitive blood tests or brain scans for bipolar disorder; diagnosis relies on a comprehensive clinical assessment, including psychiatric history, family history, collateral reports, and DSM-5-TR-based interviews. Screening tools like the MDQ can aid identification but have limited sensitivity, especially for bipolar II, and should not be used alone for diagnosis (Wang et al., 2015).

3. What does the bipolar spectrum entail?

The bipolar spectrum includes bipolar I, bipolar II, cyclothymia, and subthreshold mood disorders, acknowledging that important mood instability can exist beyond standard DSM categories. Recognizing these conditions can guide treatment and enhance outcomes.

4. What are common comorbidities, and how do they affect treatment?

Common psychiatric comorbidities of bipolar disorder are anxiety disorders (~75%), substance use disorders (33–50%), ADHD (10–25%), OCD (6–16%), and borderline personality disorder (15%). These comorbidities complicate diagnosis, worsen prognosis, and require tailored treatments. Treatment typically begins with mood stabilization, then addresses comorbidities using interventions that do not destabilize mood.

5. What are the most effective treatment strategies?

Combining evidence-based medications (like lithium, lamotrigine, quetiapine, and lurasidone) with psychosocial therapies (such as psychoeducation, CBT, IPSRT, and FFT) yields the best results. Maintaining regular sleep, routines, exercise, and avoiding substances helps stabilize mood. Individualized plans and strong collaboration with providers are crucial for positive outcomes (Yatham et al., 2018).

References

1. Amerio, A., Odone, A., Marchesi, C., & Ghaemi, S. N. (2024). Obsessive–compulsive disorder as an epiphenomenon of comorbid bipolar disorder? An updated systematic review. Journal of Clinical Medicine, 13(5), 1230. https://doi.org/10.3390/jcm13051230

2. American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders (5th ed., text rev.). American Psychiatric Association Publishing.

3. Asherson, P., Leaver, L., Engel, L., & Adamou, M. (2023). Management strategies for borderline personality disorder and bipolar disorder comorbidities in adults with ADHD: A narrative review. Current Medical Research and Opinion, 39(11), 1497–1510.

4. Carta, M. G., Catena, G., & Pinna, F. L. (2025). The inaccuracy of the Mood Disorder Questionnaire for bipolar disorder in a community sample: From the "DYMERS" construct toward a new instrument for detecting vulnerable conditions. Journal of Clinical Medicine, 14(9), 3017. https://doi.org/10.3390/jcm14093017

5. Huang, H., Nissen, N., Lim, C. T., Gören, J. L., Spottswood, M., & Huang, H. (2022). Treating bipolar disorder in primary care: Diagnosis, pharmacology, and management. International Journal of General Medicine, 15, 8299–8314. https://doi.org/10.2147/IJGM.S386875

6. Karaahmet, E., Konuk, N., Dalkilic, A., Saracli, O., & Atasoy, N. (2022). Adult attention-deficit/hyperactivity disorder and bipolar disorder: Diagnostic and management challenges. European Psychiatry, 65(S1), S482–S483.

7. Keramatian, K., Chakrabarty, T., Engel, L., Yatham, L. N., et al. (2023). The CANMAT and ISBD guidelines for the treatment of bipolar disorder: Summary and a 2023 update of evidence. FOCUS: The Journal of Lifelong Learning in Psychiatry, 21(4), 413–425. https://doi.org/10.1176/appi.focus.20230009

8. Lukmanji, S., Maier, A., & Engel, L. (2022). Population-based psychiatric comorbidity in children and adolescents with autism spectrum disorder: A meta-analysis. Frontiers in Psychiatry, 13, 856208. https://doi.org/10.3389/fpsyt.2022.856208

9. Merikangas, K. R., Jin, R., He, J. P., et al. (2011). Prevalence and correlates of bipolar spectrum disorder in the World Mental Health Survey Initiative. Archives of General Psychiatry, 68(3), 241–251. https://doi.org/10.1001/archgenpsychiatry.2011.12

10. Oliva, V., Fico, G., De Prisco, M., Gonda, X., Rosa, A. R., & Vieta, E. (2024). Bipolar disorders: An update on critical aspects. The Lancet Regional Health – Europe, 48, 101135. https://doi.org/10.1016/j.lanepe.2024.101135

11. Perrotta, G., Ferro, F., & Ferrara, D. (2021). ADHD and bipolar disorder in adulthood: Clinical and treatment implications. Medicina, 57(5), 466. https://doi.org/10.3390/medicina57050466

12. Prigent Bertin, C., et al. (2025). Clinical interplay between autism spectrum disorder and bipolar disorder: A narrative review. Trends in Psychiatry and Psychotherapy. Advance online publication. https://doi.org/10.47626/2237-6089-2024-0XXX

13. Schiweck, C., Arteaga-Henriquez, G., Aichholzer, M., Edwin Thanarajah, S., et al. (2021). Comorbidity of ADHD and adult bipolar disorder: A systematic review and meta-analysis. Neuroscience & Biobehavioral Reviews, 124, 100–123.

14. Solmi, M., Miola, A., Capone, F., & Pallottino, S. (2025). Short communication on proposed treatment directions in bipolar disorder: A psychotherapy perspective. Journal of Clinical Medicine, 14(6), 1857. https://doi.org/10.3390/jcm14061857

15. Wang, Y. C., Bai, Y. M., et al. (2015). The validity of the Mood Disorder Questionnaire for screening bipolar disorder: A meta-analysis. Depression and Anxiety, 32(7), 527–538. https://doi.org/10.1002/da.22374

16. Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., ... & Berk, M. (2018). Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disorders, 20(2), 97–170. https://doi.org/10.1111/bdi.12609

17. Yatham, L. N., Chakrabarty, T., Bond, D. J., et al. (2021). Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) recommendations for the management of patients with bipolar disorder with mixed presentations. Bipolar Disorders, 23(7), 767–788. https://doi.org/10.1111/bdi.13135